Augmenting Ankle Plantarflexor Function in Cerebral Palsy

This study is looking at new ways to help children and young adults with cerebral palsy (CP) walk better. It's testing a lightweight robotic device called Biomotum Spark, which can either help or resist ankle movement. Researchers want to see if using this device for training, or to make walking easier, improves ankle muscle function and walking ability. They will compare it to standard physical therapy, standard gait training (walking practice), and ankle foot orthoses (braces). The study will measure changes in walking speed immediately after the intervention, and again at 2 weeks and 12 weeks later. You may be able to join if you are 8 to 21 years old, have CP affecting your ankles, and can walk at least 30 feet with or without help. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 36 participants. The study aims to compare different interventions for improving walking in individuals with cerebral palsy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks after the intervention to measure changes in walking speed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05154253

Augmenting Ankle Plantarflexor Function in Cerebral Palsy

Recruiting
PHASE1Ages 8–21InterventionalTreatment
Northern Arizona University
~36 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:Biomotum Spark: Robotic ankle assistanceBiomotum Spark: Robotic ankle resistanceStandard gait trainingAnkle foot orthosisStandard physical therapyStandard walking

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in preferred walking speed
Measured over Immediately after the intervention
+31 more outcomes measured
Cerebral Palsy
1 sites across 1 states
Minnesota1
  • Zach F Lerner, PhD · PRINCIPAL_INVESTIGATOR · Northern Arizona University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages between 8 and 21 years old, inclusive. Diagnosis of CP and a pathological gait pattern caused by ankle dysfunction.
Able to understand and follow simple directions (based on parent report, if needed) and walk at least 30 feet with or without a walking aid (Gross Motor Function Classification System (GMFCS) Level I-III).
At least 20° of passive plantar-flexion range of motion.

Exclusion

Concurrent treatment other than those assigned during the study.
A condition other than CP that would affect safe participation.
Surgical intervention within 6 months of participation.
  • Change in preferred walking speedImmediately after the intervention

    Participant's preferred walking speed compared after to before the intervention

  • Change in preferred walking speed2 weeks after the intervention

    Participant's preferred walking speed compared after to before the intervention

  • Change in preferred walking speed12 weeks after the intervention

    Participant's preferred walking speed compared after to before the intervention

  • Change in similarity of plantarflexor muscle activityImmediately after the intervention

    Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

  • Change in similarity of plantarflexor muscle activity2 weeks after the intervention

    Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

  • Change in similarity of plantarflexor muscle activity12 weeks after the intervention

    Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

  • Change in 6-minute-walk-test distanceImmediately after the intervention

    Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

  • Change in 6-minute-walk-test distance2 weeks after the intervention

    Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

  • Change in 6-minute-walk-test distance12 weeks after the intervention

    Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

  • Change in variance in muscle activityImmediately after the intervention

    Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

  • Change in variance in muscle activity2 weeks after the intervention

    Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

  • Change in variance in muscle activity12 weeks after the intervention

    Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

  • Change in stride lengthImmediately after the intervention

    Participant stride length during walking. Longer stride length is desired.

  • Change in stride length2 weeks after the intervention

    Participant stride length during walking. Longer stride length is desired.

  • Change in stride length12 weeks after the intervention

    Participant stride length during walking. Longer stride length is desired.

  • Change in stride-to-stride variability stride lengthImmediately after the intervention

    Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

  • Change in stride-to-stride variability stride length2 weeks after the intervention

    Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

  • Change in stride-to-stride variability stride length12 weeks after the intervention

    Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

  • Change in walking postureImmediately after the intervention

    Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

  • Change in walking posture2 weeks after the intervention

    Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

  • Change in walking posture12 weeks after the intervention

    Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

  • Change in Gross Motor Function Measure-66 sec. D&EImmediately after the intervention

    Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

  • Change in Gross Motor Function Measure-66 sec. D&E2 weeks after the intervention

    Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

  • Change in Gross Motor Function Measure-66 sec. D&E12 weeks after the intervention

    Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

  • Change in plantar-flexor strengthImmediately after the intervention

    Plantar-flexor muscle strength measured via hand-held dynamometry.

  • Change in plantar-flexor strength2 weeks after the intervention

    Plantar-flexor muscle strength measured via hand-held dynamometry.

  • Change in plantar-flexor strength12 weeks after the intervention

    Plantar-flexor muscle strength measured via hand-held dynamometry.

  • Distance traveled1 day

    Distance traveled during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols.

  • Metabolic cost of transport from indirect calorimetry1 day

    Metabolic cost estimated from a wearable indirect calorimetry system during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols

  • Subject perceived exertion1 day

    Subject perceived exertion (validated pictorial pediatric exertion scale). The scale is from 1-10, where a higher number indicates more effort.

  • Average muscle activity1 day

    Average stance-phase plantar flexor muscle activity assessed through surface electromyography of the soleus muscle.

  • Heart Rate1 day

    Average heart rate during each testing condition measured via chest-mounted heart rate monitor.